Therapy Areas: Oncology
Apotex launches generic version of INLYTA in US market
17 November 2026 -

Canadian pharmaceutical company Apotex Health Corp (TSX:APTX) announced on Monday the US launch of Axitinib Tablets, 1 mg and 5 mg, the first generic version of Pfizer's INLYTA, a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

Renal cell carcinoma is the most common type of kidney cancer in adults and accounts for approximately 90% of kidney cancer diagnoses. Axitinab Tablets provide an additional FDA-approved treatment option for appropriate patients with advanced RCC following failure of one prior systemic therapy.

Axitinib Tablets are supplied as 1 mg tablets in bottles of 180 (NDC 60505-4427-8) and 5 mg tablets in bottles of 60 (NDC 60505-4428-6).

Login
Username:

Password: